Cargando…

Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19

Although the importance of virus-specific cytotoxic T lymphocytes (CTL) in virus clearance is evident in COVID-19, the characteristics of virus-specific CTLs related to disease severity have not been fully explored. Here we show that the phenotype of virus-specific CTLs against immunoprevalent epito...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogura, Hideki, Gohda, Jin, Lu, Xiuyuan, Yamamoto, Mizuki, Takesue, Yoshio, Son, Aoi, Doi, Sadayuki, Matsushita, Kazuyuki, Isobe, Fumitaka, Fukuda, Yoshihiro, Huang, Tai-Ping, Ueno, Takamasa, Mambo, Naomi, Murakami, Hiromoto, Kawaguchi, Yasushi, Inoue, Jun-ichiro, Shirai, Kunihiro, Yamasaki, Sho, Hirata, Jun-Ichi, Ishido, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758236/
https://www.ncbi.nlm.nih.gov/pubmed/36526616
http://dx.doi.org/10.1038/s41467-022-34655-1
_version_ 1784851998966808576
author Ogura, Hideki
Gohda, Jin
Lu, Xiuyuan
Yamamoto, Mizuki
Takesue, Yoshio
Son, Aoi
Doi, Sadayuki
Matsushita, Kazuyuki
Isobe, Fumitaka
Fukuda, Yoshihiro
Huang, Tai-Ping
Ueno, Takamasa
Mambo, Naomi
Murakami, Hiromoto
Kawaguchi, Yasushi
Inoue, Jun-ichiro
Shirai, Kunihiro
Yamasaki, Sho
Hirata, Jun-Ichi
Ishido, Satoshi
author_facet Ogura, Hideki
Gohda, Jin
Lu, Xiuyuan
Yamamoto, Mizuki
Takesue, Yoshio
Son, Aoi
Doi, Sadayuki
Matsushita, Kazuyuki
Isobe, Fumitaka
Fukuda, Yoshihiro
Huang, Tai-Ping
Ueno, Takamasa
Mambo, Naomi
Murakami, Hiromoto
Kawaguchi, Yasushi
Inoue, Jun-ichiro
Shirai, Kunihiro
Yamasaki, Sho
Hirata, Jun-Ichi
Ishido, Satoshi
author_sort Ogura, Hideki
collection PubMed
description Although the importance of virus-specific cytotoxic T lymphocytes (CTL) in virus clearance is evident in COVID-19, the characteristics of virus-specific CTLs related to disease severity have not been fully explored. Here we show that the phenotype of virus-specific CTLs against immunoprevalent epitopes in COVID-19 convalescents might differ according to the course of the disease. We establish a cellular screening method that uses artificial antigen presenting cells, expressing HLA-A(*)24:02, the costimulatory molecule 4-1BBL, SARS-CoV-2 structural proteins S, M, and N and non-structural proteins ORF3a and nsp6/ORF1a. The screen implicates SARS-CoV-2 M protein as a frequent target of IFNγ secreting CD8(+) T cells, and identifies M(198–206) as an immunoprevalent epitope in our cohort of HLA-A(*)24:02 positive convalescent COVID-19 patients recovering from mild, moderate and severe disease. Further exploration of M(198–206)-specific CD8(+) T cells with single cell RNA sequencing reveals public TCRs in virus-specific CD8(+) T cells, and shows an exhausted phenotype with less differentiated status in cells from the severe group compared to cells from the moderate group. In summary, this study describes a method to identify T cell epitopes, indicate that dysfunction of virus-specific CTLs might be an important determinant of clinical outcomes.
format Online
Article
Text
id pubmed-9758236
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-97582362022-12-18 Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19 Ogura, Hideki Gohda, Jin Lu, Xiuyuan Yamamoto, Mizuki Takesue, Yoshio Son, Aoi Doi, Sadayuki Matsushita, Kazuyuki Isobe, Fumitaka Fukuda, Yoshihiro Huang, Tai-Ping Ueno, Takamasa Mambo, Naomi Murakami, Hiromoto Kawaguchi, Yasushi Inoue, Jun-ichiro Shirai, Kunihiro Yamasaki, Sho Hirata, Jun-Ichi Ishido, Satoshi Nat Commun Article Although the importance of virus-specific cytotoxic T lymphocytes (CTL) in virus clearance is evident in COVID-19, the characteristics of virus-specific CTLs related to disease severity have not been fully explored. Here we show that the phenotype of virus-specific CTLs against immunoprevalent epitopes in COVID-19 convalescents might differ according to the course of the disease. We establish a cellular screening method that uses artificial antigen presenting cells, expressing HLA-A(*)24:02, the costimulatory molecule 4-1BBL, SARS-CoV-2 structural proteins S, M, and N and non-structural proteins ORF3a and nsp6/ORF1a. The screen implicates SARS-CoV-2 M protein as a frequent target of IFNγ secreting CD8(+) T cells, and identifies M(198–206) as an immunoprevalent epitope in our cohort of HLA-A(*)24:02 positive convalescent COVID-19 patients recovering from mild, moderate and severe disease. Further exploration of M(198–206)-specific CD8(+) T cells with single cell RNA sequencing reveals public TCRs in virus-specific CD8(+) T cells, and shows an exhausted phenotype with less differentiated status in cells from the severe group compared to cells from the moderate group. In summary, this study describes a method to identify T cell epitopes, indicate that dysfunction of virus-specific CTLs might be an important determinant of clinical outcomes. Nature Publishing Group UK 2022-12-16 /pmc/articles/PMC9758236/ /pubmed/36526616 http://dx.doi.org/10.1038/s41467-022-34655-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ogura, Hideki
Gohda, Jin
Lu, Xiuyuan
Yamamoto, Mizuki
Takesue, Yoshio
Son, Aoi
Doi, Sadayuki
Matsushita, Kazuyuki
Isobe, Fumitaka
Fukuda, Yoshihiro
Huang, Tai-Ping
Ueno, Takamasa
Mambo, Naomi
Murakami, Hiromoto
Kawaguchi, Yasushi
Inoue, Jun-ichiro
Shirai, Kunihiro
Yamasaki, Sho
Hirata, Jun-Ichi
Ishido, Satoshi
Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19
title Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19
title_full Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19
title_fullStr Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19
title_full_unstemmed Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19
title_short Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19
title_sort dysfunctional sars-cov-2-m protein-specific cytotoxic t lymphocytes in patients recovering from severe covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758236/
https://www.ncbi.nlm.nih.gov/pubmed/36526616
http://dx.doi.org/10.1038/s41467-022-34655-1
work_keys_str_mv AT ogurahideki dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT gohdajin dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT luxiuyuan dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT yamamotomizuki dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT takesueyoshio dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT sonaoi dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT doisadayuki dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT matsushitakazuyuki dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT isobefumitaka dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT fukudayoshihiro dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT huangtaiping dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT uenotakamasa dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT mambonaomi dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT murakamihiromoto dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT kawaguchiyasushi dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT inouejunichiro dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT shiraikunihiro dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT yamasakisho dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT hiratajunichi dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19
AT ishidosatoshi dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19